News

Research led by MetaCurUm Biotech’s founder, Professor Maréne Landström at Umeå University, has been published in Signal Transduction and Targeted Therapy. The study provides important new insights into how aggressive cancers spread and strengthens the […]

MetaCurUm AB has been awarded 1 million SEK in the second phase of Vinnova’s initiative “Acceleration of Deep Tech Companies”. The support will enable MetaCurUm to progress its innovative cancer therapy toward preclinical and future

A research team from Umeå and Uppsala university led by Maréne Landström, founder of MetaCurUm Biotech, has identified a panel of seven blood-based protein biomarkers that can accurately detect clear cell renal cell carcinoma (ccRCC),

MetaCurUm Biotech AB has been awarded one million SEK from the Swedish Innovation Agency, Vinnova, under the “Acceleration of Deeptech Companies 2024” initiative.“This support is crucial for us as it brings us closer to securing

Maréne Landström, a professor of pathology at Umeå University, was named Sweden’s Cancer Researcher of the Year for 2024. Her groundbreaking research is currently being developed into a cancer treatment by the company MetaCurUm, which

Maréne Landström, the founder of MetaCurUm Biotech AB, has been awarded SEK 4.8 million from the Swedish Research Council and SEK 5.25 million from the Swedish Cancer Society for her research at Umeå University. Her

The research group led by Professor Maréne Landström at the Department of Medical Biosciences, in collaboration with a team at Uppsala University, has made a unique discovery. The results of their study have been published

Earlier this year, Maarten de Château invested capital in MetaCurUm, becoming a part-owner of the company. He is now set to assume the role of the new CEO. “I am honored to take on this

MetaCurUm has successfully secured SEK 15 million in capital investment, with Nylöf Holding and Chateau Holding stepping in as the primary investors. Maarten de Château and Urban Paulsson, both with extensive experience in drug development,

Peter Frank joins MetaCurUm as Project Manager. Peter has 20 years of experience in Biologics/ATMP and biotech. He’s held positions at GE Healthcare and Galderma as project manager, responsible for CMC, taking a compound through